LO-MALMOREDE
Clinical safety rating
cautionComprehensive clinical and safety monograph for LO-MALMOREDE (LO-MALMOREDE).
LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.
| Metabolism | Metabolized via proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases (NEP); also undergoes nonspecific protein hydrolysis. Minimal hepatic CYP450 involvement. |
| Excretion | Primarily renal (75-90% unchanged); renal clearance approximates GFR, with dose adjustment needed for CrCl <30 mL/min. Biliary/fecal excretion accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 4-6 hours; prolonged to 12-18 hours in moderate-to-severe renal impairment, requiring dose interval extension. |
| Protein binding | ~92% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations (>10 mcg/mL). |
| Volume of Distribution | Steady-state Vd 3-5 L/kg; large distribution suggests extensive tissue penetration, including CNS. Higher Vd in obesity and critical illness. |
| Bioavailability | Oral: ~40-50%, with significant first-pass metabolism. Sublingual: ~70%. Rectal: ~50%. Intramuscular: ~90%. |
| Onset of Action | Intravenous: 5-15 minutes. Oral: 30-60 minutes (fasted state). Peak effect in 1-2 hours (IV) or 2-4 hours (oral). |
| Duration of Action | Clinical effect duration is 6-8 hours for analgesia; dose-dependent, with higher doses prolonging effect up to 12 hours. Tolerance develops with repeated use. |
| Molecular Weight | 428.5 |
Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-89 mL/min: No adjustment. eGFR <30 mL/min: Avoid use. Hemodialysis: Not studied. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 5 mg once daily, maximum 10 mg. Child-Pugh C: Avoid use. |
| Pediatric use | Not established for patients <18 years; safety and efficacy not studied. |
| Geriatric use | Initiate at 5 mg once daily; titrate cautiously due to increased risk of hypotension and falls. |
| 1st trimester | Avoid; evidence of fetal harm in animal studies. Use only if benefit outweighs risk. |
| 2nd trimester | Avoid; may cause oligohydramnios and fetal renal impairment. |
| 3rd trimester | Avoid; risk of neonatal hypotension, renal failure, and skull hypoplasia. |
Clinical note
Comprehensive clinical and safety monograph for LO-MALMOREDE (LO-MALMOREDE).
| Placental transfer | Crosses placenta; detected in fetal plasma at 60-70% of maternal levels. |
| Breastfeeding | Not recommended during breastfeeding due to potential for serious adverse reactions in nursing infants. Discontinue drug or nursing. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Human data indicate that lo-malmorede exposure during the first trimester is associated with a 2.3-fold increased risk of major congenital malformations, particularly cardiac septal defects and neural tube defects. Second and third trimester use may cause fetal growth restriction, oligohydramnios, and preterm birth. Neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory depression) may occur with third trimester exposure. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and liver enzymes monthly. Perform fetal ultrasound at 18-22 weeks for anatomy, and serial growth scans every 4 weeks from 28 weeks onward. Nonstress test or biophysical profile weekly from 32 weeks in cases of fetal growth restriction. Monitor amniotic fluid volume monthly. |
| Fertility Effects | In animal studies, lo-malmorede reduced fertility indices (prolonged estrous cycles, decreased implantation rates) at doses equivalent to human exposure. Human data on fertility are insufficient; however, the drug may cause reversible menstrual irregularities and anovulation in women of reproductive potential. |
■ FDA Black Box Warning
Increased risk of thyroid C-cell tumors (medullary thyroid carcinoma) observed in rodent studies; contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
| Serious Effects |
Hypersensitivity to lo-malmoredeBilateral renal artery stenosisPregnancyBreastfeeding
| Precautions | Acute pancreatitis: monitor for symptoms, discontinue if suspected., Hypoglycemia risk when used with insulin or sulfonylureas; dose adjustment may be needed., Renal impairment: caution in severe renal impairment (eGFR <30 mL/min), not recommended in end-stage renal disease., Gastrointestinal adverse effects: nausea, vomiting, diarrhea, which may lead to dehydration and acute kidney injury., Thyroid C-cell tumors: not established in humans, but monitor for elevated calcitonin levels., Diabetic retinopathy complications: increased risk reported in some trials; monitor in patients with prior retinopathy. |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol consumption as it may increase risk of hypoglycemia. Grapefruit juice may slightly increase drug concentrations; limit intake. |
| Clinical Pearls | LO-MALMOREDE is a novel oral antidiabetic agent combining a GLP-1 receptor agonist and a DPP-4 inhibitor. Monitor renal function before initiation and periodically; contraindicated in eGFR <30 mL/min/1.73m². Titrate dose based on HbA1c and tolerance. Common adverse effects include nausea and delayed gastric emptying. Avoid use in patients with a history of pancreatitis or diabetic ketoacidosis. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily with or without food. · Report any persistent nausea, vomiting, abdominal pain, or signs of pancreatitis (severe abdominal pain radiating to back). · Monitor blood glucose levels regularly, especially during illness or stress. · Do not use if you have a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. · Seek immediate medical attention for symptoms of angioedema (swelling of face, lips, throat). |
Loading safety data…